---

Related Articles:

Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.

1981-02-01

[Eur. J. Clin. Pharmacol. 19(3) , 217-23, (1981)]

Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.

1998-03-01

[Pharmacol. Toxicol. 82(3) , 157-60, (1998)]

Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.

1988-01-01

[Acta Oncol. 27(5) , 583-9, (1988)]

Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine.

1986-10-01

[Acta Anaesthesiol. Scand. 30(7) , 502-6, (1986)]

Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.

1982-01-01

[Acta Pharmacol. Toxicol. (Copenh.) 50(1) , 78-80, (1982)]